Ask the Experts

Dr. Ronald Bowsher, chief scientist for BioPharma Services at Millipore Corporation, has many years experience in the development, validation and application of ligand binding assays to support assessments of novel biomarkers in support of drug development. Early in his career, Dr. Bowsher recognized the potential of immunoassays to improve throughput and effectiveness for all steps of clinical drug development, including target validation, screening, pharmacokinetic/pharmacodynamic analysis, and post-clinical evaluation. Dr. Bowsher designed quantitative immunoassays against metabolic pathway biomarkers, such as insulin, proinsulin, and insulin-like growth factor II (IGF-II), facilitating treatment for diabetes and other endocrine or metabolic diseases. Dr. Bowsher has applied his immunoassay expertise to biotherapeutics, small molecule drugs, diagnostics, and immunogenicity testing for Eli Lilly and Company and for customers of LINCO Diagnostics, Inc. (now part of Millipore Corporation). Simultaneously, Dr. Bowsher promoted bioanalytical methods validation for novel biomarker testing through numerous publications, committee leaderships, formalizing an AAPS training course and consultancy to numerous pharmaceutical and biotech companies. Under Dr. Bowsher’s leadership, Millipore’s BioPharma Services have empowered its customers decision-making capabilities for drug safety and efficacy by providing novel biomarker solutions.